Get the latest Science News and Discoveries

Sarcoma clinical trial funded by stand up to cancer reduces risk of relapse by 43% - EurekAlert


For the last three decades, breakthroughs have been sparse for soft tissue sarcomas, which are rare cancers that affect muscles, fat and other connective tissues. Today, a global team of researchers funded by a Stand Up To Cancer® (SU2C) grant announced clinical trial results that point to a new immunotherapy treatment option for two of the most common types of soft tissue sarcoma in adults, a breakthrough that reduces the risk of relapse by 43% at two years and will likely impact clinical practice for these cancer types.

None

Get the Android app

Or read this on Eureka Alert

Read more on:

Photo of Risk

Risk

Photo of relapse

relapse

Photo of Cancer

Cancer

Related news:

News photo

Presence of carpal tunnel syndrome may indicate a high risk of developing cardiac amyloidosis, according to study ... - EurekAlert

News photo

Five projects will receive funding to advance understanding of ocean systems in a changing climate - EurekAlert

News photo

Ancient Greece expert named to American Academy of Arts and Sciences - EurekAlert